insights_auto
Outlook: 63.3% bullish·3.3% bearish
Go to analysischevron_right
INO:NASDAQ
Inovio Pharmaceuticals Inc
$1.48
arrow_upward
+1.72%(+0.025) 1D
$1.46
arrow_downward
-0.96% (-0.014)bedtimeAfter hours
Closed: Nov 11, 3:54:54 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INO...
Open
$1.37
High
$1.48
Low
$1.30
Mkt. cap
249.17M
Avg. vol.
18.79M
Volume
9.73M
52-wk high
$2.72
52-wk low
$0.57
EPS
-$1.17
Beta
1.71
Shares outstanding
103.40M
No. of employees
112
Open
$1.37
High
$1.48
Low
$1.30
Mkt. cap
249.17M
Avg. vol.
18.79M
Volume
9.73M
52-wk high
$2.72
52-wk low
$0.57
EPS
-$1.17
Beta
1.71
Shares outstanding
103.40M
No. of employees
112
News stories
From web sources and news partners
GuruFocus
·
5 hours ago
INO Reiterated by Piper Sandler -- Price Target Lowered to $6.00
Yahoo Finance
·
8 hours ago
INOVIO to Participate in Upcoming Investor Conferences
GuruFocus
·
17 hours ago
FMR LLC Adds Inovio Pharmaceuticals Inc (INO) Shares -- Stock Looks 625% Overvalued on GF Value
TradingView
·
18 hours ago
Inovio Pharmaceuticals Q3 Earnings Call Highlights
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees112
Founded1999
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteinovio.com